4D Molecular Therapeutics Inc’s recently made public that its Chief Legal Officer Bizily Scott unloaded Company’s shares for reported $8165.0 on Sep 16 ’24. In the deal valued at $16.33 per share,500 shares were sold. As a result of this transaction, Bizily Scott now holds 6,781 shares worth roughly $55604.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Bizily Scott sold 500 shares, generating $7,500 in total proceeds. Upon selling the shares at $15.00, the Chief Legal Officer now owns 6,781 shares.
Before that, Bizily Scott sold 1,750 shares. 4D Molecular Therapeutics Inc shares valued at $47,442 were divested by the Chief Legal Officer at a price of $27.11 per share. As a result of the transaction, Bizily Scott now holds 6,781 shares, worth roughly $55604.2.
Cantor Fitzgerald downgraded its 4D Molecular Therapeutics Inc [FDMT] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. Barclays began covering FDMT with “an Overweight” recommendation on April 15, 2024.
Price Performance Review of FDMT
On Tuesday, 4D Molecular Therapeutics Inc [NASDAQ:FDMT] saw its stock fall -4.32% to $8.20. Over the last five days, the stock has lost -0.73%. 4D Molecular Therapeutics Inc shares have fallen nearly -59.53% since the year began. Nevertheless, the stocks have fallen -21.68% over the past one year. While a 52-week high of $36.25 was reached on 03/27/24, a 52-week low of $7.90 was recorded on 10/23/24. SMA at 50 days reached $12.14, while 200 days put it at $21.05.
Levels Of Support And Resistance For FDMT Stock
The 24-hour chart illustrates a support level at 8.01, which if violated will result in even more drops to 7.83. On the upside, there is a resistance level at 8.50. A further resistance level may holdings at 8.81. The Relative Strength Index (RSI) on the 14-day chart is 29.77, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.26, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.42%. Stochastics %K at 27.43% indicates the stock is a holding.
How much short interest is there in 4D Molecular Therapeutics Inc?
A steep rise in short interest was recorded in 4D Molecular Therapeutics Inc stocks on 2024-10-15, dropping by 27204.0 shares to a total of 9.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 9.52 million shares. There was a decline of -0.29%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 26, 2023 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
